Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Reducing Adverse Event Risk

Posted on September 25th, 2017 by in Pharma R&D

In 2012, the U.S. Food and Drug Administration (FDA) provided draft guidance for the industry on drug interaction studies, stating that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.” Continue reading “Reducing Adverse Event Risk” »

Assessing DDI Risk in the Digital Age

Posted on August 9th, 2017 by in Pharmacovigilance

pills pic for SD case study
In their 2012 Drug Regulations, the U.S. Food and Drug Administration recommended that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development.”

Continue reading “Assessing DDI Risk in the Digital Age” »

Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis

Posted on July 5th, 2017 by in Pharma R&D

These days, there is a lot of focus on nutraceuticals and ‘natural products’, derived from nature or alternately synthesized as ‘nature-identical compounds’ and used in nutraceuticals products. Continue reading “Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis” »

The Value of Drug–Drug Interaction Risk Assessments

Posted on June 28th, 2017 by in Pharma R&D

Should a drug candidate move on to pre-clinical and clinical trials? It’s a question that every pharmaceutical developer must face, and the earlier they can answer it, the better in terms of use of time and effort. Continue reading “The Value of Drug–Drug Interaction Risk Assessments” »

  1. 1
  2. 2
  3. 3